The conundrum of alpha-synuclein antibody failures in Parkinson’s disease: a narrative review of mechanisms and alternative metabolic hypotheses
Therapeutic Advances in Neurological Disorders
Published online on July 14, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Parkinson’s disease (PD) remains the second most common neurodegenerative disorder globally, yet disease-modifying therapies remain elusive. The past decade of therapeutic development has been dominated by the hypothesis that alpha-synuclein aggregates ...
Parkinson’s disease (PD) remains the second most common neurodegenerative disorder globally, yet disease-modifying therapies remain elusive. The past decade of therapeutic development has been dominated by the hypothesis that alpha-synuclein aggregates ...